Top

Published in:

Open Access 01-12-2019 | Diabetes | Original investigation

Association between serum haptoglobin and carotid arterial functions: usefulness of a targeted metabolomics approach

Authors: Shiyun Wang, Jie Wang, Rong Zhang, Aihua Zhao, Xiaojiao Zheng, Dandan Yan, Feng Jiang, Wei Jia, Cheng Hu, Weiping Jia

Published in: Cardiovascular Diabetology | Issue 1/2019

Abstract

Background

Serum haptoglobin (Hp) has been closely associated with cardio-cerebrovascular diseases. We investigated a metabolic profile associated with circulating Hp and carotid arterial functions via a targeted metabolomics approach to provide insight into potential mechanisms.

Methods

A total of 240 participants, including 120 patients with type 2 diabetes mellitus (T2DM) and 120 non-diabetes mellitus (non-DM) subjects were recruited in this study. Targeted metabolic profiles of serum metabolites were determined using an AbsoluteIDQ™ p180 Kit (BIOCRATES Life Sciences AG, Innsbruck, Austria). Ultrasound of the bilateral common carotid artery was used to measure intima-media thickness and inter-adventitial diameter. Serum Hp levels were tested by enzyme-linked immunosorbent assay.

Results

Serum Hp levels in T2DM patients and non-DM subjects were 103.40 (72.46, 131.99) mg/dL and 100.20 (53.99, 140.66) mg/dL, respectively. Significant differences of 19 metabolites and 17 metabolites were found among serum Hp tertiles in T2DM patients and non-DM subjects, respectively (P < 0.05). Of these, phosphatidylcholine acyl-alkyl C32:2 (PC ae C32:2) was the common metabolite observed in two populations, which was associated with the serum Hp groups and lipid traits (P < 0.05). Furthermore, the metabolite ratios of two acidic amino acids, including aspartate to PC ae C32:2 (Asp/PC ae C32:2) and glutamate to PC ae C32:2 (Glu/PC ae C32:2) were correlated with serum Hp, carotid arterial functions and other biochemical index in both populations significantly (P < 0.05).

Conclusions

Targeted metabolomics analyses might provide a new insight into the potential mechanisms underlying the association between serum Hp and carotid arterial functions.

Available only for authorised users

Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197–223.PubMedCrossRef

Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care. 1998;21(7):1138–45.PubMedCrossRef

Newman JD, Schwartzbard AZ, Weintraub HS, Goldberg IJ, Berger JS. Primary prevention of cardiovascular disease in diabetes mellitus. J Am Coll Cardiol. 2017;70(7):883–93.PubMedPubMedCentralCrossRef

Mellbin LG, Anselmino M, Ryden L. Diabetes, prediabetes and cardiovascular risk. Eur J Cardiovasc Prev Rehabil. 2010;17(Suppl 1):S9–14.PubMedCrossRef

Bao X, Borne Y, Johnson L, Muhammad IF, Persson M, Niu K, Engstrom G. Comparing the inflammatory profiles for incidence of diabetes mellitus and cardiovascular diseases: a prospective study exploring the ‘common soil’ hypothesis. Cardiovasc Diabetol. 2018;17(1):87.PubMedPubMedCentralCrossRef

Ijas P, Saksi J, Soinne L, Tuimala J, Jauhiainen M, Jula A, Kahonen M, Kesaniemi YA, Kovanen PT, Kaste M, et al. Haptoglobin 2 allele associates with unstable carotid plaque and major cardiovascular events. Atherosclerosis. 2013;230(2):228–34.PubMedCrossRef

Dalan R, Liew H, Goh LL, Gao X, Chew DE, Boehm BO, Leow MK. The haptoglobin 2-2 genotype is associated with inflammation and carotid artery intima-media thickness. Diabetes Vasc Dis Res. 2016;13(5):373–6.CrossRef

Orchard TJ, Backlund JC, Costacou T, Cleary P, Lopes-Virella M, Levy AP, Lachin JM, Group DER. Haptoglobin 2-2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). J Diabetes Complications. 2016;30(8):1577–84.PubMedPubMedCentralCrossRef

Jansen H, Samani NJ, Schunkert H. Mendelian randomization studies in coronary artery disease. Eur Heart J. 2014;35(29):1917–24.PubMedCrossRef

10.

Jimenez-Rosales A, Amaya-Chavez A, Dominguez Garcia MV, Camarillo-Romero E, Huitron Bravo GG, Cruz AM. Association of inflammatory and oxidative stress biomarkers in subjects with cardiovascular risk. Am J Ther. 2013;20(4):422–31.PubMedCrossRef

11.

Xuan Y, Gao X, Holleczek B, Brenner H, Schottker B. Prediction of myocardial infarction, stroke and cardiovascular mortality with urinary biomarkers of oxidative stress: results from a large cohort study. Int J Cardiol. 2018;273:223–9. https://doi.org/10.1016/j.ijcard.2018.08.002 PubMedCrossRef

12.

Wang S, Wang J, Zhang R, Wang T, Yan D, He Z, Jiang F, Hu C, Jia W. Mendelian randomization analysis to assess a causal effect of haptoglobin on macroangiopathy in Chinese type 2 diabetes patients. Cardiovasc Diabetol. 2018;17(1):14.PubMedPubMedCentralCrossRef

13.

Andersen CBF, Stodkilde K, Saederup KL, Kuhlee A, Raunser S, Graversen JH, Moestrup SK. Haptoglobin. Antioxid Redox Signal. 2017;26(14):814–31.PubMedCrossRef

14.

Alayash AI, Andersen CB, Moestrup SK, Bulow L. Haptoglobin: the hemoglobin detoxifier in plasma. Trends Biotechnol. 2013;31(1):2–3.PubMedCrossRef

15.

Can U, Buyukinan M, Guzelant A, Ugur A, Karaibrahimoglu A, Yabanciun S. Investigation of the inflammatory biomarkers of metabolic syndrome in adolescents. J Pediatr Endocrinol Metab. 2016;29(11):1277–83.PubMed

16.

Awadallah S, Madkour M, Hamidi RA, Alwafa EA, Hattab M, Zakkour B, Al-Matroushi A, Ahmed E, Al-Kitbi M. Plasma levels of apolipoprotein A1 and lecithin: cholesterol acyltransferase in type 2 diabetes mellitus: correlations with haptoglobin phenotypes. Diabetes Metab Syndr. 2017;11(Suppl 2):S543–6.PubMedCrossRef

17.

Melander O, Modrego J, Zamorano-Leon JJ, Santos-Sancho JM, Lahera V, Lopez-Farre AJ. New circulating biomarkers for predicting cardiovascular death in healthy population. J Cell Mol Med. 2015;19(10):2489–99.PubMedPubMedCentralCrossRef

18.

Cigliano L, Pugliese CR, Spagnuolo MS, Palumbo R, Abrescia P. Haptoglobin binds the antiatherogenic protein apolipoprotein E—impairment of apolipoprotein E stimulation of both lecithin:cholesterol acyltransferase activity and cholesterol uptake by hepatocytes. FEBS J. 2009;276(21):6158–71.PubMedCrossRef

19.

Sas KM, Karnovsky A, Michailidis G, Pennathur S. Metabolomics and diabetes: analytical and computational approaches. Diabetes. 2015;64(3):718–32.PubMedPubMedCentralCrossRef

20.

Newgard CB. Metabolomics and metabolic diseases: where do we stand? Cell Metab. 2017;25(1):43–56.PubMedCrossRef

21.

Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016;17(7):451–9.PubMedPubMedCentralCrossRef

22.

Lu J, Xie G, Jia W, Jia W. Metabolomics in human type 2 diabetes research. Front Med. 2013;7(1):4–13.PubMedCrossRef

23.

Klupczynska A, Derezinski P, Kokot ZJ. Metabolomics in medical sciences-trends, challenges and perspectives. Acta Pol Pharm. 2015;72(4):629–41.PubMed

24.

Chen P, Hou X, Hu G, Wei L, Jiao L, Wang H, Chen S, Wu J, Bao Y, Jia W. Abdominal subcutaneous adipose tissue: a favorable adipose depot for diabetes? Cardiovasc Diabetol. 2018;17(1):93.PubMedPubMedCentralCrossRef

25.

Qiu Y, Zhou B, Su M, Baxter S, Zheng X, Zhao X, Yen Y, Jia W. Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast cancer patients. Int J Mol Sci. 2013;14(4):8047–61.PubMedPubMedCentralCrossRef

26.

Suhre K, Raffler J, Kastenmuller G. Biochemical insights from population studies with genetics and metabolomics. Arch Biochem Biophys. 2016;589:168–76.PubMedCrossRef

27.

Molnos S, Wahl S, Haid M, Eekhoff EMW, Pool R, Floegel A, Deelen J, Much D, Prehn C, Breier M, et al. Metabolite ratios as potential biomarkers for type 2 diabetes: a DIRECT study. Diabetologia. 2018;61(1):117–29.PubMedCrossRef

28.

Stegemann C, Pechlaner R, Willeit P, Langley SR, Mangino M, Mayr U, Menni C, Moayyeri A, Santer P, Rungger G, et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation. 2014;129(18):1821–31.PubMedCrossRef

29.

Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57–63.PubMedPubMedCentralCrossRef

30.

Glomset JA. The mechanism of the plasma cholesterol esterification reaction: plasma fatty acid transferase. Biochim Biophys Acta. 1962;65:128–35.PubMedCrossRef

31.

Chen L, Liang B, Froese DE, Liu S, Wong JT, Tran K, Hatch GM, Mymin D, Kroeger EA, Man RY, et al. Oxidative modification of low density lipoprotein in normal and hyperlipidemic patients: effect of lysophosphatidylcholine composition on vascular relaxation. J Lipid Res. 1997;38(3):546–53.PubMed

32.

Oka H, Kugiyama K, Doi H, Matsumura T, Shibata H, Miles LA, Sugiyama S, Yasue H. Lysophosphatidylcholine induces urokinase-type plasminogen activator and its receptor in human macrophages partly through redox-sensitive pathway. Arterioscler Thromb Vasc Biol. 2000;20(1):244–50.PubMedCrossRef

33.

Kim M, Jung S, Kim SY, Lee SH, Lee JH. Prehypertension-associated elevation in circulating lysophosphatidlycholines, Lp-PLA2 activity, and oxidative stress. PLoS ONE. 2014;9(5):e96735.PubMedPubMedCentralCrossRef

34.

Li X, Fang P, Li Y, Kuo YM, Andrews AJ, Nanayakkara G, Johnson C, Fu H, Shan H, Du F, et al. Mitochondrial reactive oxygen species mediate lysophosphatidylcholine-induced endothelial cell activation. Arterioscler Thromb Vasc Biol. 2016;36(6):1090–100.PubMedPubMedCentralCrossRef

35.

Takahashi M, Okazaki H, Ogata Y, Takeuchi K, Ikeda U, Shimada K. Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. Atherosclerosis. 2002;161(2):387–94.PubMedCrossRef

36.

Paapstel K, Kals J, Eha J, Tootsi K, Ottas A, Piir A, Jakobson M, Lieberg J, Zilmer M. Inverse relations of serum phosphatidylcholines and lysophosphatidylcholines with vascular damage and heart rate in patients with atherosclerosis. Nutr Metab Cardiovasc Dis. 2018;28(1):44–52.PubMedCrossRef

37.

Mannheim D, Herrmann J, Versari D, Gossl M, Meyer FB, McConnell JP, Lerman LO, Lerman A. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke. 2008;39(5):1448–55.PubMedPubMedCentralCrossRef

38.

Nakhjavani M, Asgharani F, Khalilzadeh O, Esteghamati A, Ghaneei A, Morteza A, Anvari M. Oxidized low-density lipoprotein is negatively correlated with lecithin–cholesterol acyltransferase activity in type 2 diabetes mellitus. Am J Med Sci. 2011;341(2):92–5.PubMedCrossRef

39.

Eigenbrodt ML, Bursac Z, Rose KM, Couper DJ, Tracy RE, Evans GW, Brancati FL, Mehta JL. Common carotid arterial interadventitial distance (diameter) as an indicator of the damaging effects of age and atherosclerosis, a cross-sectional study of the Atherosclerosis Risk in Community Cohort Limited Access Data (ARICLAD), 1987-89. Cardiovasc Ultrasound. 2006;4:1.PubMedPubMedCentralCrossRef

40.

Naqvi TZ, Lee MS. Carotid intima-media thickness and plaque in cardiovascular risk assessment. JACC Cardiovasc Imaging. 2014;7(10):1025–38.CrossRef

41.

Saba L, Araki T, Kumar PK, Rajan J, Lavra F, Ikeda N, Sharma AM, Shafique S, Nicolaides A, Laird JR, et al. Carotid inter-adventitial diameter is more strongly related to plaque score than lumen diameter: an automated tool for stroke analysis. J Clin Ultrasound. 2016;44(4):210–20.PubMedCrossRef

42.

Kozakova M, Morizzo C, La Carrubba S, Fabiani I, Della Latta D, Jamagidze J, Chiappino D, Di Bello V, Palombo C. Associations between common carotid artery diameter, Framingham risk score and cardiovascular events. Nutr Metab Cardiovasc Dis. 2017;27(4):329–34.PubMedCrossRef

43.

Polak JF, Sacco RL, Post WS, Vaidya D, Arnan MK, O’Leary DH. Incident stroke is associated with common carotid artery diameter and not common carotid artery intima-media thickness. Stroke. 2014;45(5):1442–6.PubMedPubMedCentralCrossRef

44.

Eigenbrodt ML, Sukhija R, Rose KM, Tracy RE, Couper DJ, Evans GW, Bursac Z, Mehta JL. Common carotid artery wall thickness and external diameter as predictors of prevalent and incident cardiac events in a large population study. Cardiovasc Ultrasound. 2007;5:11.PubMedPubMedCentralCrossRef

45.

Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316(22):1371–5.PubMedCrossRef

46.

Polak JF, Wong Q, Johnson WC, Bluemke DA, Harrington A, O’Leary DH, Yanez ND. Associations of cardiovascular risk factors, carotid intima-media thickness and left ventricular mass with inter-adventitial diameters of the common carotid artery: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis. 2011;218(2):344–9.PubMedPubMedCentralCrossRef

47.

Petersen AK, Krumsiek J, Wagele B, Theis FJ, Wichmann HE, Gieger C, Suhre K. On the hypothesis-free testing of metabolite ratios in genome-wide and metabolome-wide association studies. BMC Bioinform. 2012;13:120.CrossRef

48.

Zhai G, Wang-Sattler R, Hart DJ, Arden NK, Hakim AJ, Illig T, Spector TD. Serum branched-chain amino acid to histidine ratio: a novel metabolomic biomarker of knee osteoarthritis. Ann Rheum Dis. 2010;69(6):1227–31.PubMedCrossRef

49.

Illig T, Gieger C, Zhai G, Romisch-Margl W, Wang-Sattler R, Prehn C, Altmaier E, Kastenmuller G, Kato BS, Mewes HW, et al. A genome-wide perspective of genetic variation in human metabolism. Nat Genet. 2010;42(2):137–41.PubMedCrossRef

50.

Shi Y, Liu L, Yu Y, Long Y, Zheng H. Acidic amino acids: a new-type of enzyme mimics with application to biosensing and evaluating of antioxidant behaviour. Spectrochim Acta A Mol Biomol Spectrosc. 2018;201:367–75.PubMedCrossRef

51.

Aftring RP, Manos PN, Buse MG. Catabolism of branched-chain amino acids by diaphragm muscles of fasted and diabetic rats. Metabolism. 1985;34(8):702–11.PubMedCrossRef

52.

Adeva-Andany MM, Lopez-Maside L, Donapetry-Garcia C, Fernandez-Fernandez C, Sixto-Leal C. Enzymes involved in branched-chain amino acid metabolism in humans. Amino Acids. 2017;49(6):1005–28.PubMedCrossRef

53.

Katakami N, Mita T, Irie Y, Takahara M, Matsuoka TA, Gosho M, Watada H, Shimomura I, Sitagliptin Preventive study of Intima-media thickness Evaluation C. Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE). Cardiovasc Diabetol. 2018;17(1):24.PubMedPubMedCentralCrossRef

54.

Bhanpuri NH, Hallberg SJ, Williams PT, McKenzie AL, Ballard KD, Campbell WW, McCarter JP, Phinney SD, Volek JS. Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study. Cardiovasc Diabetol. 2018;17(1):56.PubMedPubMedCentralCrossRef

55.

Rizzo M, Rizvi AA, Patti AM, Nikolic D, Giglio RV, Castellino G, Li Volti G, Caprio M, Montalto G, Provenzano V, et al. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol. 2016;15(1):162.PubMedPubMedCentralCrossRef

Title: Association between serum haptoglobin and carotid arterial functions: usefulness of a targeted metabolomics approach
Authors: Shiyun Wang
Jie Wang
Rong Zhang
Aihua Zhao
Xiaojiao Zheng
Dandan Yan
Feng Jiang
Wei Jia
Cheng Hu
Weiping Jia
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Diabetes
Type 2 Diabetes
Published in: Cardiovascular Diabetology / Issue 1/2019
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/s12933-019-0808-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Association between serum haptoglobin and carotid arterial functions: usefulness of a targeted metabolomics approach

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Targeting the glucagon receptor improves cardiac function and enhances insulin sensitivity following a myocardial infarction

MiR-30c/PGC-1β protects against diabetic cardiomyopathy via PPARα

Changes in behaviors after diagnosis of type 2 diabetes and 10-year incidence of cardiovascular disease and mortality

Epicardial fat tissue in patients with diabetes mellitus: a systematic review and meta-analysis

Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy

Phenotyping diabetic cardiomyopathy in Europeans and South Asians

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page